Giuseppe Curigliano, President Elect of ESMO and Member of the Editorial Board at OncoDaily, shared a post on LinkedIn:
“Extending ET with OFS in premenopausal patients with node-positive eBC after 5 years of LHRHa treatment is associated with a clinically meaningful reduction in both invasive and distant breast cancer recurrences. A must read to answer an important clinical question!”
Title: Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort Study
Authors: Carmine Valenza, Yue Zheng, Monica Milano, Dario Trapani, Elisa Giordano, Lorenzo Guidi, Pier Paolo Maria Berton Giachetti, Laura Boldrini, Grazia Castellano, Jalissa Katrini, Bianca Malagutti, Gabriele Antonarelli, Fabio Conforti, Eleonora Pagan, Vincenzo Bagnardi, Gregory J. Kirkner, Claudia Sangalli, Kate E. Dibble, Marco Colleoni, Meredith M. Regan, Elisabetta Munzone, Giuseppe Curigliano, Ann H. Partridge
Giuseppe Curigliano Recognized among The 100 Most Influential People in Oncology in 2025
